Brazil-based biotechnology company Biomm (BVMF: BIOM3) has announced that it has in-licensed the late-stage biosimilar candidate BAT2206 from China’s Bio-Thera Solutions (SHA: 688177). This biosimilar candidate references Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary Janssen’s immunosuppressant Stelara (ustekinumab). The agreement builds upon a previous licensing and supply deal from 2020 for BAT1706, Bio-Thera’s biosimilar version of Roche’s (SWX: ROG) Avastin (bevacizumab).
Deal Terms and Global Development Strategy
Under the terms of the agreement, Biomm will be responsible for filing BAT2206 for approval in Brazil, capitalizing on its strong local presence, sales, and marketing capabilities. Concurrently, Bio-Thera will handle the commercial supply of the product and complete the global development of BAT2206 before submitting it for regulatory review in China, Europe, and the US.
Biomm Enhances Local Production Capabilities
In a parallel development, Biomm has received a good manufacturing practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for the production and bottling of sterile solutions at its biologic drugs site in Minas Gerais. This certification is a significant milestone, as the site has an annual production capacity of up to 20 million flasks and 20 million syringes, demonstrating Biomm’s commitment to enhancing its local production capabilities and meeting the demand for biosimilar drugs in the region.-Fineline Info & Tech
